Recent MRNS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 09:05:18 PM
- Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results • Business Wire • 11/12/2024 09:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/02/2024 12:30:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 12:05:19 PM
- Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives • Business Wire • 10/24/2024 12:00:00 PM
- Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting • Business Wire • 10/17/2024 11:00:00 AM
- Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens • Business Wire • 10/15/2024 08:00:00 PM
- Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting • Business Wire • 10/09/2024 11:00:00 AM
- Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) • Business Wire • 10/08/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 11:56:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 12:15:20 PM
- Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day • Business Wire • 09/20/2024 12:00:00 PM
- Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 • Business Wire • 09/12/2024 12:00:00 PM
- Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 12:00:00 PM
- Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 • Business Wire • 08/19/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:09:04 AM
- Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results • Business Wire • 08/13/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:06 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM